跳至主要内容
临床试验/NCT05870657
NCT05870657已完成不适用

Adherence and Persistence to Inclisiran Among Early Users in Germany

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 1,109 人开始时间: 2022年2月16日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,109
试验地点
1
主要终点
Number and percentage of patients with at least 5 months of potential follow-up who were prescribed a second dose of inclisiran

研究概览

简要总结

The present study was a descriptive, non-interventional, retrospective cohort study aimed at evaluating early data on adherence, persistence, and treatment patterns among patients receiving inclisiran and other lipid-lowering therapies (LLT) in a real-world setting in Germany. Analysis was carried out using the IQVIA™ LRx database.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Study subjects ≥18 years old who were prescribed an inclisiran dose.

排除标准

  • 未提供

结局指标

主要结局

Number and percentage of patients with at least 5 months of potential follow-up who were prescribed a second dose of inclisiran

时间窗: 8 months

Median time between first and second prescribed doses

时间窗: 8 months

Percentage of patients who were prescribed a second dose of inclisiran between 1 and 6 months after prescription of first dose

时间窗: 8 months

次要结局

  • Age and gender characteristics(6 months)
  • Age and gender distribution(6 months)
  • Prescriber specialty distribution for patients(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验